Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Common Equity (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Common Equity readings, the most recent being $11.4 million for Q4 2023.

  • On a quarterly basis, Common Equity rose 111.13% to $11.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $11.4 million, a 111.13% increase, with the full-year FY2023 number at $11.4 million, up 111.13% from a year prior.
  • Common Equity hit $11.4 million in Q4 2023 for Elicio Therapeutics, down from $13.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $92.4 million in Q1 2021 to a low of -$109.9 million in Q1 2023.
  • Median Common Equity over the past 4 years was -$56.1 million (2020), compared with a mean of -$31.5 million.
  • Biggest five-year swings in Common Equity: soared 401.35% in 2021 and later crashed 248.34% in 2022.
  • Elicio Therapeutics' Common Equity stood at -$90.4 million in 2020, then increased by 17.59% to -$74.5 million in 2021, then crashed by 37.04% to -$102.1 million in 2022, then soared by 111.13% to $11.4 million in 2023.
  • The last three reported values for Common Equity were $11.4 million (Q4 2023), $13.3 million (Q3 2023), and $23.6 million (Q2 2023) per Business Quant data.